Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, blinded, placebo-controlled Phase 2 study of LMB763 in NASH
2016-002833-31Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing LMB763 with Placebo (2 arms). Primary endpoints: Change from baseline in ALT, Safety and tolerability of LMB763 and 1 more. Started Dec 2016; status: terminated.
02
Drugs
nidufexor
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2016-002833-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002833-31.